Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL17460309 | 0.77 | GAA (0.47) | LMNAGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL28042294 | 0.77 | CYP2D6 (0.50) | LMNAGAACYP2D6CYP1A2CYP3A4 | |
| SCHEMBL1802065 | 0.75 | CYP3A4 (0.52) | LMNAGAAALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL7654483 | 0.73 | CYP3A4 (0.50) | LMNAGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL8400939 | 0.72 | SRC (0.54) | LMNAALDH1A1KMT2AKDM4ECYP2D6 | |
| SCHEMBL7332031 | 0.71 | SLC6A4 (0.57) | CYP2D6CYP1A2CYP3A4CYP2C19KCNH2 | |
| SCHEMBL7480934 | 0.70 | CYP2D6 (0.47) | LMNAGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL5859624 | 0.70 | CYP1A2 (0.47) | LMNAGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL974061 | 0.70 | SRC (0.52) | LMNAALDH1A1KMT2AKDM4ECYP2D6 | |
| SCHEMBL11404609 | 0.70 | SRC (0.52) | LMNAALDH1A1KMT2AKDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515142-B2 | Intermediates of aromatic amidine derivatives which have anticoagulation action | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020062033-A1 | Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-23 | — | — | US | disclosed |
| US-6337405-B1 | MULTISTAGE REACTION OF PYRROLE SUBSTITUTED WITH SULFONATE GROUPS AND HYDROXYPHENYLACETIC ACID | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6252088-B1 | COUPLING A NITRILE CONTAININ NAPHTHALENE COMPOUND WITH A COMPOUND CONTAINING PROPIONIC ACID GROUP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0936215-A1 | PROCESS FOR PREPARING 2-PHENYL-3-NAPHTHYLPROPIONIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062033-A1 | Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives | PROC, F12, F2 | LMNA 283/4885GAA 2260/4885ALDH1A1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.